Leuven-based Coultreon Biopharma, formerly Onco3R Therapeutics, is set to advance its lead candidate, the SIK3 inhibitor COL-5671, into Phase II trials following a successful financing round led by Sofinnova Investments. COL-5671 aims to target inflammatory pathways in autoimmune diseases, exhibiting a favorable safety profile in early trials. The therapy uniquely reduces pro-inflammatory cytokines while boosting the immunoregulatory cytokine IL-10, offering a potentially more durable disease control than current treatments. The financing round reflects significant investor interest in innovative immunomodulatory approaches, emphasizing the growing potential of Coultreon’s pipeline.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://european-biotechnology.com/latest-news/coultreon-bags-us125m-for-autoimmune-pipeline/
